Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.76 |
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796417 | 0.87 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2AHTR7 | |
| SCHEMBL29057926 | 0.82 | HTR6 (0.74) | HTR6DRD2DRD3HTR1AHTR2A | |
| SCHEMBL6274917 | 0.81 | HTR6 (0.50) | HTR6DRD2HTR2A | |
| SCHEMBL28311487 | 0.80 | HTR6 (0.71) | HTR6DRD2DRD3HTR1AHTR2A | |
| SCHEMBL4659559 | 0.80 | HTR6 (0.71) | HTR6DRD2DRD3ADRB1HTR1A | |
| SCHEMBL30394401 | 0.80 | HTR6 (0.71) | HTR6DRD2DRD3HTR1AHTR2A | |
| SCHEMBL28311460 | 0.80 | HTR6 (0.71) | HTR6DRD2DRD3HTR1AHTR2A | |
| SCHEMBL5763068 | 0.77 | HTR6 (0.64) | HTR6DRD2HTR1AHTR2AHTR7 | |
| SCHEMBL5203017 | 0.76 | HTR6 (0.77) | HTR6DRD2HTR1AHTR2AHTR7 | |
| SCHEMBL29058052 | 0.76 | HTR6 (0.58) | HTR6DRD2DRD3ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608635-B1 | PHENYL SULFONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2009-09-16 | — | — | EP | claimed |
| US-20090012099-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-08 | — | — | US | claimed |
| US-7439245-B2 | e.g. 1-(3-Phenylsulfonyl-phenyl)piperazine; serotonin receptor modulator; anxiolytic agent, antidepressant, cognition activator; schizophrenia, obesity, Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | claimed |
| US-20080214571-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2008-09-04 | — | — | US | claimed |
| US-7262188-B2 | Phenyl sulfone derivatives and their use in the treatment of CNS disorders | GLAXO GROUP LIMITED (GB) | 2007-08-28 | — | — | US | claimed |
| US-20060281757-A1 | Phenyl sulfone derivatives and their use in the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2006-12-14 | — | — | US | claimed |
| EP-1608635-A1 | PHENYL SULFONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-12-28 | — | — | EP | claimed |
| WO-2004080986-A1 | PHENYL SULFONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | claimed |
| EP-1608635-B1 | PHENYL SULFONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2009-09-16 | — | — | EP | disclosed |
| US-20090012099-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-08 | — | — | US | disclosed |
| US-7439245-B2 | e.g. 1-(3-Phenylsulfonyl-phenyl)piperazine; serotonin receptor modulator; anxiolytic agent, antidepressant, cognition activator; schizophrenia, obesity, Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-20080214571-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2008-09-04 | — | — | US | disclosed |
| US-20070275979-A1 | Novel Compounds | GLAXOGROUP LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7262188-B2 | Phenyl sulfone derivatives and their use in the treatment of CNS disorders | GLAXO GROUP LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-20060281757-A1 | Phenyl sulfone derivatives and their use in the treatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1608635-A1 | PHENYL SULFONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004080986-A1 | PHENYL SULFONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012099-A1 | Novel Compounds | PSEN2, PSEN1, BACE1 | HTR6 269/4885DRD2 2391/4885DRD3 2963/4885 |
| US-20080214571-A1 | NOVEL COMPOUNDS | NPSR1, GABRE, HTR2B | HTR6 4/4885DRD2 163/4885DRD3 381/4885 |
| US-20070275979-A1 | Novel Compounds | CNR2, CNR1, GRIN2C | HTR6 57/4885DRD2 129/4885DRD3 161/4885 |
| US-20060281757-A1 | Phenyl sulfone derivatives and their use in the treatment of cns disorders | PMP22, SNCA, SLC6A3 | HTR6 105/4885DRD2 279/4885DRD3 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.